Microsporidiosis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (13 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Microsporidiosis}} | {{Microsporidiosis}} | ||
{{CMG}}; {{AE}}{{AY}} | |||
{{CMG}} | ==Overview== | ||
Secondary prevention strategies following microsporidiosis include continuing treatment indefinitely after [[ocular]] microsporidiosis and continued [[HIV AIDS medical therapy|HAART]] for [[HIV]] patients. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
The following measures are effective for preventing recurrence: | |||
Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or [[relapse]] might follow treatment discontinuation ('''BIII'''). Whether treatment can be safely discontinued after immune restoration with [[ART]] is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their [[CD4+ T lymphocyte]] counts to levels >200 cells/µL after [[ART]] ('''CIII'''). | *Treatment for [[ocular]] microsporidiosis should be continued indefinitely because recurrence or [[relapse]] might follow treatment discontinuation ('''BIII''').<ref name="urlCDC - DPDx - Microsporidiosis - Laboratory Diagnosis">{{cite web |url=https://www.cdc.gov/dpdx/microsporidiosis/dx.html |title=CDC - DPDx - Microsporidiosis - Laboratory Diagnosis |format= |work= |accessdate=}}</ref> | ||
*Whether treatment can be safely discontinued after [[immune]] restoration with [[HIV AIDS medical therapy|antiretroviral therapy]] ([[HIV AIDS medical therapy|ART]]) is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary [[prophylaxis]] (chronic maintenance therapy) for other [[Opportunistic infection|opportunistic infections]] during advanced [[Human Immunodeficiency Virus (HIV)|HIV-1]] disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their [[CD4+ T cells|CD4<sup>+</sup> T lymphocyte]] counts to levels >200 cells/µL after [[HIV AIDS medical therapy|ART]] ('''CIII'''). | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | |||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | [[Category:Infectious disease]] | ||
[[Category: | [[Category:Ophthalmology]] | ||
[[Category: | [[Category:Neurology]] | ||
[[Category:Dermatology]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 22:43, 29 July 2020
|
Microsporidiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Microsporidiosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Microsporidiosis secondary prevention |
|
Risk calculators and risk factors for Microsporidiosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
Secondary prevention strategies following microsporidiosis include continuing treatment indefinitely after ocular microsporidiosis and continued HAART for HIV patients.
Secondary Prevention
The following measures are effective for preventing recurrence:
- Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or relapse might follow treatment discontinuation (BIII).[1]
- Whether treatment can be safely discontinued after immune restoration with antiretroviral therapy (ART) is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their CD4+ T lymphocyte counts to levels >200 cells/µL after ART (CIII).